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BACKGROUND: Cardiovascular disease is associated with epigenomic 
changes in the heart; however, the endogenous structure of cardiac 
myocyte chromatin has never been determined.
METHODS: To investigate the mechanisms of epigenomic function in 
the heart, genome-wide chromatin conformation capture (Hi-C) and 
DNA sequencing were performed in adult cardiac myocytes following 
development of pressure overload–induced hypertrophy. Mice with 
cardiac-specific deletion of CTCF (a ubiquitous chromatin structural 
protein) were generated to explore the role of this protein in chromatin 
structure and cardiac phenotype. Transcriptome analyses by RNA-seq were 
conducted as a functional readout of the epigenomic structural changes.
RESULTS: Depletion of CTCF was sufficient to induce heart failure 
in mice, and human patients with heart failure receiving mechanical 
unloading via left ventricular assist devices show increased CTCF 
abundance. Chromatin structural analyses revealed interactions within 
the cardiac myocyte genome at 5-kb resolution, enabling examination 
of intra- and interchromosomal events, and providing a resource for 
future cardiac epigenomic investigations. Pressure overload or CTCF 
depletion selectively altered boundary strength between topologically 
associating domains and A/B compartmentalization, measurements 
of genome accessibility. Heart failure involved decreased stability of 
chromatin interactions around disease-causing genes. In addition, 
pressure overload or CTCF depletion remodeled long-range interactions 
of cardiac enhancers, resulting in a significant decrease in local chromatin 
interactions around these functional elements.
CONCLUSIONS: These findings provide a high-resolution chromatin 
architecture resource for cardiac epigenomic investigations and 
demonstrate that global structural remodeling of chromatin underpins 
heart failure. The newly identified principles of endogenous chromatin 
structure have key implications for epigenetic therapy.
High-Resolution Mapping of Chromatin 
Conformation in Cardiac Myocytes Reveals 
Structural Remodeling of the Epigenome 
in Heart Failure
© 2017 The Authors. Circulation 
is published on behalf of the 
American Heart Association, Inc., 
by Wolters Kluwer Health, Inc. This 
is an open access article under the 
terms of the Creative Commons 
Attribution Non-Commercial-
NoDerivs License, which permits 
use, distribution, and reproduction 
in any medium, provided that the 
original work is properly cited, 
the use is noncommercial, and no 
modifications or adaptations are 
made.
Correspondence to: Thomas 
M. Vondriska, PhD, David Geffen 
School of Medicine, University 
of California, Los Angeles, 
BH 557 CHS, Department of 
Anesthesiology, 650 Charles Young 
Drive, Los Angeles, CA 90095. 
E-mail tvondriska@mednet.ucla.edu
Sources of Funding, see page 1623
Key Words: epigenomics 
◼ genomics ◼ heart failure 
◼ hypertrophy
Manuel Rosa-Garrido, PhD
Douglas J. Chapski, BS
Anthony D. Schmitt, PhD
Todd H. Kimball, BS
Elaheh Karbassi, PhD
Emma Monte, PhD
Enrique Balderas, PhD
Matteo Pellegrini, PhD
Tsai-Ting Shih, BS
Elizabeth Soehalim, BS
David Liem, MD, PhD
Peipei Ping, PhD
Niels J. Galjart, PhD
Shuxun Ren, MD
Yibin Wang, PhD
Bing Ren, PhD
Thomas M. Vondriska, PhD
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on N
ovem
ber 6, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Rosa-Garrido et al
October 24, 2017 Circulation. 2017;136:1613–1625. DOI: 10.1161/CIRCULATIONAHA.117.0294301614
Heart failure is a devastating condition that affects 6.5 million adults in the United States.1 Although it is a multiorgan disease, heart failure is driven 
by changes in cardiac myocyte biology, including cell 
death, calcium handling, myofilament function, me-
tabolism, and other factors. Underlying this complex 
cellular malfunction are gene expression changes, or-
chestrated by a network of transcription factors and 
chromatin-remodeling enzymes.2–5 Despite this knowl-
edge, the basic folding principles of the cardiac myo-
cyte epigenome have never been revealed, and the role 
of chromatin structural changes in cardiovascular dis-
ease is unknown.
Correct packaging of the genome within the nucle-
us determines appropriate gene expression and cellu-
lar function.6 Nucleosomes are differentially positioned 
along chromosomes, a process controlled by chromatin 
remodelers and histone-modifying enzymes.7 Tracks 
of nucleosomes adopt fiberlike structures that in turn 
compose the 3-dimensional architecture of endog-
enous chromatin, a process that is necessary for orderly 
storage and controlled accessibility of genetic informa-
tion.8
Chromatin modifications are engaged in a develop-
mentally tuned manner to enable both the unidirec-
tional procession of differentiation and transcriptome 
stability. Cells use enhancers,9 distal regulatory regions 
that host histone posttranslational modifications and 
have an increasingly appreciated role in cardiovascu-
lar disease,10–12 and chromatin-binding proteins that, 
together with transcription factors, sculpt the tran-
scriptome. Among chromatin structural proteins, CTCF 
has been attributed a key role in modulating genome 
architecture13 and maintaining regions of genome ac-
cessibility across cell types.14 Once cellular lineages 
have been established, prevailing proteomic programs 
ensure that, on division, the correct epigenomic land-
scape is reestablished in daughter cells, maintaining 
lineage fidelity. An underexplored area of chromatin bi-
ology is how epigenomic stability is maintained in vivo 
when cells have exited the cell cycle. Adult mammalian 
cardiac myocytes do not readily divide, and the heart 
lacks robust regenerative capacity. Although epigenetic 
transitions in cardiovascular development have been in-
vestigated in cell culture,15,16 much less is known about 
the adult heart. Previous studies have demonstrated a 
role for histone-modifying enzymes3 and the readers of 
these modifications,17 but whether 3-dimensional con-
figuration of the genome contributes to heart disease 
remains to be determined.
Recent investigations have demonstrated the exis-
tence of topologically associating domains (TADs) as 
regions of chromatin that exhibit a higher level of lo-
cal interactions. These structural neighborhoods of the 
genome may facilitate coregulation of gene expres-
sion and are shared across many biological conditions, 
suggesting they are fundamental features of the ge-
nome.8,18 However, the specific nature of interactions 
within and between these TADs in cardiac cells, and the 
additional hierarchical levels of chromatin packaging 
(including local interactions, long-range interactions, 
enhancer-gene interactions, and chromatin looping) 
used in the cardiac myocyte nucleus in health and dis-
ease, are unknown.
The findings of the present study establish a high-
resolution, genome-wide resource of endogenous 
chromatin interactions in cardiac myocytes, which can 
be used by future investigations to examine virtually 
any genomic locus. In addition, the results demonstrate 
specific areas of the epigenome that are structurally re-
organized in pressure overload–induced heart disease, 
revealing how enhancers interact with disease-causing 
genes and the role of chromatin looping in cardiac 
gene expression. Using a physiologically relevant form 
of afterload-induced cardiac disease (plus a lineage tar-
geted loss-of-function CTCF knockout [KO] mouse as 
a unique model for comparison), this investigation ex-
amines the role of global epigenome structure in heart 
failure.
METHODS
All animal studies were approved by the UCLA Animal 
Research Committee in compliance with the National 
Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Human samples used in this study were procured 
in the Ronald Reagan Medical Center at UCLA following 
patient consent according to institutional review board–
approved protocol. This study used DNA from adult mouse 
Clinical Perspective
What Is New?
• Chromatin capture and DNA sequencing were 
used to determine the endogenous structure of the 
cardiac myocyte epigenome.
• Physical interactions between regulatory elements 
and cardiac disease genes have been determined 
in basal and disease settings.
• The role of the chromatin structural protein CTCF 
was examined by using an in vivo loss-of-function 
model, revealing its role in chromatin organization 
and disease.
What Are the Clinical Implications?
• Epigenomic plasticity is identified as a common 
feature of cardiac pathophysiology induced by dis-
tinct stimuli.
• Knowledge of the dynamics of genomic interac-
tions in disease may enable new strategies for ther-
apeutic intervention.
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cardiac myocytes isolated from control mice or 2 distinct dis-
ease models (pressure overload–induced hypertrophy and 
CTCF-KO) to perform chromosome conformation capture 
(Hi-C) analysis to determine endogenous chromatin structure 
(all sequencing-based studies were performed on n≥3 bio-
logical replicates per group; n values for all other end points 
are provided in figure legends). Transcriptome analyses were 
performed using RNA-seq to examine the functional read-
outs of any structural changes in the epigenome. Chromatin 
structure was then examined at multiple scales to determine 
structural units, hierarchical organization, and 3-dimensional 
regulation of accessibility and transcription.
Statistical Analyses
All sequencing-based studies were performed on n≥3 bio-
logical replicates per group; n values for all other end points 
are provided in figure legends. The statistical tests performed 
for each end point are listed in the individual figure legends, 
described in the Methods in the online-only Data Supplement 
and are summarized here: Student’s t test (see Figure  1A 
and 1E, Figures IIC, IIE, and IV in the online-only Data 
Supplement); Tukey test (see Figure 1C); Wilcoxon test (see 
Figure 2F); and Pearson correlation (Figure IIIB in the online-
only Data Supplement). For RNA-seq data, Cuffdiff was used 
to determine differential gene expression and assign P val-
ues and q values for each gene. For interaction analyses, see 
Figure 4B through 4D and Figure 5, Fit-Hi-C was used to filter 
for cis-interactions with q value <0.01, which were then used 
to map interactions.
Detailed methodology for all experiments and analyses are 
available in the online-only Data Supplement.
RESULTS
Chromosome Conformation Capture
Chromatin was purified from isolated cardiac myocytes 
and subjected to chromosome conformation capture 
(Hi-C). Mappability of reads was 63% to 65% across 
experimental groups (Figure IA in the online-only Data 
Supplement) at a depth of sequencing enabling ex-
amination of interactions with 5-kb resolution (Figure 
IB in the online-only Data Supplement). No significant 
differences were observed across experimental groups 
in terms of number of interactions analyzed, and the 
run-to-run variability was low (Figure IC in the online-
only Data Supplement). Unless otherwise noted in the 
figures, all control groups were from myocytes isolated 
from untreated adult wild-type mice (all mice used in 
this study are C57BL/6 background). With this high-
resolution resource, one can explore the physical en-
vironment of virtually any genomic locus in the cardiac 
myocyte at multiple scales including topologically asso-
ciating domains, A/B compartmentalization, chromatin 
looping, enhancer interactions, and gene interactions. 
Sequencing data have been uploaded to the National 
Center for Biotechnology Information with the GEO ac-
cession number GSE96693 and are publically available.
Loss of CTCF Causes Cardiomyopathy
A mouse line with inducible, cardiac myocyte-specific 
ablation of CTCF was generated. Mice with a loxp 
flanked Ctcf allele (Ctcfflox/flox mice) were crossed with 
mice expressing a transgenic tamoxifen-inducible Cre 
protein under the control of the α-myosin heavy chain 
promoter (MerCreMer mice). When administered 
tamoxifen in the diet for 5 weeks followed by 1 week 
on regular chow (Figure IIA, right, in the online-only 
Data Supplement), Ctcfflox/flox-MerCreMer+/– mice display 
selective excision of the targeted region of the Ctcf 
gene (Figure IIB in the online-only Data Supplement) 
and exhibit a gradual loss of the transcript in isolated 
cardiac myocytes (Figure IIC in the online-only Data 
Supplement). Further depletion in CTCF levels was as-
sociated with poor survival (Figure IID in the online-only 
Data Supplement); as a control, treatment of Ctcfwt/wt-
MerCreMer+/– mice with tamoxifen had no sustained 
effect on cardiac function or morphology (Figure IIG 
through III in the online-only Data Supplement). The 
experimental mice, Ctcfflox/flox-MerCreMer+/– animals 
treated with tamoxifen to induce CTCF depletion, had 
≈80% reduction in CTCF protein levels (Figure IIF in the 
online-only Data Supplement) and are henceforth re-
ferred to as CTCF-KO mice. A separate cohort of wild-
type mice were subjected to pressure overload stress 
(through surgical application of transverse aortic con-
striction [TAC]19) which induces heart failure through 
clinically relevant pathophysiological adaptation.
Phenotypic examination of the CTCF-KO mice re-
vealed a striking cardiomyopathy (Figure 1 and Figure 
IIG through III in the online-only Data Supplement). 
Loss of CTCF leads to impaired ejection fraction, left 
ventricular chamber dilation, and muscle hypertrophy 
at the organ and cell level (Figure 1A through 1C). The 
TAC mice, by contrast, also exhibit hypertrophy accom-
panied by more modest changes in both chamber size 
and ejection fraction, demonstrating that these animals 
(CTCF-KO and TAC mice) represent distinct pathophysi-
ological models. Examining CTCF expression in a ge-
netically heterogeneous population of wild-type mice 
revealed consistent downregulation following patho-
logical stimuli and an inverse correlation with patho-
logical measurements of heart size (Figure IIIA and IIIB 
in the online-only Data Supplement; it is interesting 
to note that CTCF protein and mRNA levels were un-
changed after TAC [data not shown], further suggest-
ing that these models of disease, although they share 
some phenotypic characteristics, have important mo-
lecular and pathophysiological distinctions). The time 
course for chamber dilation, diminished ejection frac-
tion, and CTCF depletion in CTCF-KO mice were similar 
(Figure IIC and IIIH in the online-only Data Supplement), 
and agreed with that for pathological gene activation 
(Figure IV in the online-only Data Supplement). CTCF-
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KO and TAC led to fibrotic deposition (Figure 1B, bot-
tom) and activation of known heart failure genes2 
(Figure  1D; Figure ID in the online-only Data Supple-
ment shows RNA-seq data quality statistics). Caspase-3 
cleavage assays to measure apoptosis showed no dif-
ference between CTCF-KO and control animals (Figure 
V in the online-only Data Supplement, suggesting, but 
not proving, that impairment of cardiac function is sec-
ondary to necrosis). In human heart tissues harvested 
before and after implantation of left ventricular assist 
A
B
D E F G
C
Figure 1. Loss of CTCF induces cardiac pathology.  
A, Echocardiography measurements of ejection fraction (EF) and left ventricular internal diameter at diastole or systole (LVIDd 
or LVIDs) demonstrate impairment of EF and chamber dilation in CTCF-KO (purple) and TAC (red) in comparison with  control 
(CTRL; green). Heart weight to body weight ratio (HW/BW) indicates cardiac hypertrophy in CTCF-KO and TAC mice (n≥25/
group; *P<0.01. Student’s t test). B, Picrosirius red staining shows fibrosis after CTCF depletion or TAC (n=3/group). C, Top, 
mean cardiomyocyte area (n=20 visual fields of wheat germ agglutinin–stained sections across 3 mice per condition); Bottom, 
quantitation of fibrosis from Picrosirius red sections (n=3/group; *P<0.01. Tukey HSD test). D, Stress response gene expression 
(log10(FPKM+1)). E, Real-time qPCR measurements of CTCF levels in human myocardium before and after LVAD (before values 
normalized to 1 on a per-patient basis; n=4, *P<0.01 Student’s t test, bars SD). F, Western blots of CTCF levels in individual 
patients before and after LVAD (Left); quantitation of Western blots normalized to actin on a per-patient, per-sample ba-
sis (Right). G, Left ventricular end-diastolic dimension measurements before and after LVAD. Color-coding in E through G 
indicates separate patients. Lines shifted horizontally in G for ease of viewing. FPKM indicates fragments per kb of exon per 
million mapped reads; HSD, honest significant difference; KO, knockout; LVAD, left ventricular assist devices; qPCR, quantita-
tive polymerase chain reaction; and TAC, transverse aortic constriction.
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Figure 2. High-resolution cardiac chromatin conformation analyses reveal changes in chromatin compartmentaliza-
tion and gene expression in pressure overload and CTCF-KO mice.  
A, Structure of topological associating domains (TADs) is revealed from contact frequency heatmaps showing cis-interaction 
profile on example chromosome 5 for control, TAC, and CTCF-KO chromatin. B, Strength of boundaries between TADs are dis-
played for all chromosomes comparing control and TAC (red, higher; blue, lower; Insets, example region on chromosome 10 
in control versus TAC and control versus CTCF-KO; Figure VIIA in the online-only Data Supplement shows control versus CTCF-
KO for all chromosomes). C, Quantitation of insulation score differences in control versus KO (Left) or TAC (Right). Colored 
dots indicate significant changes (gray dots show range of variation between 2 control conditions: untreated wild-type mouse 
and untreated Cre+/– mouse). D, A/B compartmentalization, an indicator of genome accessibility at individual loci, for an exam-
ple region on chromosome 5 is plotted in blue (open, A) and yellow (closed, B): CTRL A/B status on Top, CTCF-KO in Middle, 
and TAC on Bottom. E, Quantification of the genome-wide changes in A/B compartment change with CTCF depletion (Left) 
or TAC (Right). Bottom highlight only bins that change compartment; dark and light colors represent up- or downregu-
lated genes, respectively. F, Relationship of compartmentalization to gene expression is measured in TAC or CTCF-KO hearts. 
Log2(fold-change) of FPKM for the differentially expressed genes that either remain in the same compartment or that change 
compartments with CTCF depletion (Top) and TAC (Bottom). P values via Wilcoxon test; whiskers indicate (Continued ) 
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devices, which mechanically unload the heart, allowing 
reverse remodeling of diseased tissue, CTCF levels were 
increased after device implantation (Figure 1E through 
1G; see Figure VI in the online-only Data Supplement 
for patient clinical data; unavailability of healthy human 
hearts precluded the measurement of CTCF expression 
in these tissues).
Endogenous Chromatin Architecture in 
Healthy and Diseased Myocytes
We next aimed to examine the large-scale alterations 
in chromatin structure underlying heart disease in the 
mice subjected to TAC. There are several important dif-
ferences in the pathophysiology between the CTCF-KO 
and TAC mice, and thus the former is used herein as 
a type of alternate disease model to investigate simi-
larities and differences in global chromatin changes in 
different forms of heart failure. Analyses of TAD archi-
tecture in wild-type, CTCF-KO mice, or TAC mice dem-
onstrate TADs to be stable features of chromatin struc-
ture (Figure 2A; average TAD size=445 kb). The number 
of TAD boundaries across the entire genome varied by 
<2%, with 3686, 3746, and 3705 boundaries called in 
control, CTCF-KO, and pressure overload, respectively. 
Boundary strength, however, was differentially altered 
across the genome (Figure  2B shows the distribution 
across chromosomes for control versus TAC; Figure 2C 
shows quantitation; Figure VIIA in the online-only Data 
Supplement shows all chromosomes in all conditions; 
Figure VIIIA in the online-only Data Supplement shows 
principal component analysis for boundary strength). 
CTCF-KO or TAC chromatin each hosted new bound-
aries (Figure VIIIB in the online-only Data Supplement; 
new includes shifted boundaries and de novo forma-
tion; note that the local rate of change in insulation 
score determines boundary strength20).
Chromatin can be divided into active and inactive 
regions,21 called A and B compartments, respectively, 
which were affected to only a minor degree by loss 
of CTCF or TAC. Compartmentalization changes were 
sparse (Figure 2D and 2E) and ranged from <2 to ≈8% 
of interaction bins genome wide. The scale of the total 
genome changing compartmentalization was almost 
identical (≈4%) after CTCF-KO or TAC (Figure  2E). 
Changes in compartmentalization correlated positively 
with gene expression; that is, genes moving from A to 
B were downregulated and moving from B to A were 
upregulated (Figure 2F). Loss of CTCF elicited a tran-
scriptional profile that shared some (41% of genes) 
features with TAC (Figures 2G and 2H; Figure VIIIC in 
the online-only Data Supplement shows principal com-
ponent analysis of transcriptome data); both also exhib-
ited known marker gene activation (Figure 1D). Genes 
determined by ChIP-seq to harbor CTCF in their tran-
scription start sites were enriched in pathways associ-
ated with cardiac disease (Figure VIIID in the online-only 
Data Supplement).
Chromatin Looping Is Altered With CTCF-
KO or TAC
The hierarchical nature of chromatin results in a prepon-
derance of short-range interactions, while simultane-
ously necessitating long-range looping (Figure 3A). One 
such long-range interaction affected by CTCF depletion 
and TAC is shown in Figure  3B. Quantitative analysis 
shows that loss of CTCF or TAC was associated with a 
decrease in the total number of long-range loops, with-
out a gross change in loop size (Figure 3C). Of dynam-
ic loops in disease, 51% of those disappearing were 
shared between CTCF-KO and TAC, whereas only 15% 
of those appearing were shared; the raw number of 
loops lost in disease was also greater than the number 
formed (Figure 3D). In control chromatin, 37% (3056 
of 8240; Figure 3E) of loops were flanked by 2 CTCF 
peaks (78% ≥1 peak) and loss of 1 CTCF peak was suf-
ficient to destroy loops in 37% of the cases (326 of 
879; Figure 3F). Within reorganized loops, enrichment 
for genes in pathways associated with cardiovascular 
function was observed (Figure VIIIE in the online-only 
Data Supplement; a caveat here is that analysis of car-
diac myocytes may increase the chances that enriched 
ontology terms are of cardiovascular relevance).
Among total loops, a subset is responsible for bring-
ing together enhancers and promoters (Figure 3G and 
3H). In agreement with aberrant gene expression in 
both conditions (Figure  2F through 2H), lost loops in 
CTCF-KO and TAC chromatin were enriched in genes 
associated with cardiac pathology (Figure VIIIF in the 
online-only Data Supplement).
Heart Failure Involves Altered Enhancer-
Gene Interactions
Focusing more deeply on significant interactions that 
contribute to gene expression can reveal the physio-
logical implications of genomic structure. For example, 
Ppp3ca, a gene implicated in calcium-dependent sig-
naling and cardiac hypertrophy,4 exhibited a consistent 
Figure 2 Continued. interquartile range. G, Heat matrix (Top) showing number of differentially expressed genes between 
CTRL, CTCF KO, and TAC (intensity indicates number of genes). Venn diagram (Bottom) showing overlap of differentially ex-
pressed genes between CTRL versus CTCF KO and CTRL versus TAC. H, Heatmap depicting log2(KO/CTRL) and log2(TAC/CTRL) 
FPKM for the differentially expressed genes with q<0.01 (Left). CTRL indicates control; FPKM, fragments per kb of exon per 
million mapped reads; KO, knockout; and TAC, transverse aortic constriction. 
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decrease in total interactions in CTCF-KO or TAC condi-
tions (Figure 4A).
It is noteworthy that, of 9194 expressed genes for 
which significant (q<0.01) Fit-Hi-C data were available, 
60% had the same direction of change of interac-
tions in CTCF-KO and TAC conditions. Of the 40% of 
genes with unique behavior in the diseased condition, 
the majority (75%) were different because 1 of the 2 
(CTCF-KO or TAC) exhibited no change in interaction; 
25% were situations in which the change in interac-
tion was opposite between CTCF-KO and TAC. Of the 
genes with shared changes in interactions in CTCF-KO 
and TAC that also underwent differential expression 
(3651 of 5443), the vast majority (86%) experienced 
decreased local interactions (Figure 4B). These findings 
support a trend in which more fluid chromatin interac-
tions are associated with gene expression and where 
alterations in expression (when they occur) after per-
turbation are more likely to be in the same direction in 
CTCF-KO and TAC in contrast with control. Figure 4C 
shows the top 40 differentially expressed genes selected 
for the number of interactions in the control condition, 
demonstrating a consistent decrease in interactions in 
CTCF-KO and TAC.
Distinct mechanisms of gene regulation were associ-
ated with distinct changes in chromatin microenviron-
A
C
E F G H
D
B
Figure 3. Short- and long-range chromatin interactions, and stable chromatin looping, are altered after pressure 
overload or CTCF-KO.  
A, Schematic displaying that loops are demarcated by 2 anchors and contain regions of high-frequency interactions, indicated 
by the colored circles. B, The bioinformatic tool Juicebox is used to display an example loop that is lost with CTCF depletion 
(Middle) and TAC (Right). C, Quantitation of the phenomenon in B across genome, showing number of chromatin loops 
(Left), number of genes within loops (Middle), and loop sizes (Right; CTRL, green; CTCF-KO, purple; TAC, red). D, Overlap 
of loops only appearing in CTCF-KO or TAC in comparison with CTRL (Left); overlap of loops that disappear in CTCF-KO and 
TAC (Right). E, CTRL loops in which zero (green), one (gray), or both (yellow) anchors overlap with a CTCF peak. F, CTRL 
loops that lose ≥1 CTCF peak during CTCF depletion (blue) and CTRL loops that keep both CTCF peaks during CTCF depletion 
(red). Darker shade indicates loops that were preserved with CTCF depletion, whereas lighter color indicates loops that were 
lost. G, Schematic demonstrating types of alterations in looping architecture that can occur, including loss of loops mediating 
enhancer-promoter interactions (Top), no change (Middle), or formation (Bottom). Enhancers are orange, promoters green, 
and genes blue. H, Quantification of changes in enhancer-promoter loops. CTRL indicates control; KO, knockout; and TAC, 
transverse aortic constriction.
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ment, represented in 3 example genes (Figure 4D). Ex-
pression of Nppa (Figure 4D, left; the top is the control 
interaction matrix, the middle has specific interactions 
colored by significance, and the bottom has RNA-seq 
expression tracks), a known marker for heart failure 
in mice and humans,2 was increased in CTCF-KO and 
TAC. Nearby local interactions are dense but relatively 
unchanging, whereas those impinging on the Nppa 
gene (demarcated by vertical lines) are decreased. Ex-
pression of Kcnd2, a potassium channel implicated in 
sudden death,22 was downregulated, and the locus ex-
hibited a notable decrease in long-range interactions in 
Figure 4. Chromatin architecture is remodeled around cardiac genes during disease.  
A, As an example cardiac disease gene with changing long-range, intrachromosomal contacts, the sample-specific interac-
tions emanating from Ppp3ca in control and after CTCF depletion or TAC are shown (q<0.01; 40-Kb resolution; outer circle, 
chromosome position; black, mm10 genes). B, Examining gene expression data for all 5443 genes with shared interaction 
behavior between CTCF-KO and TAC, 3651 genes were found to be differentially expressed in the same direction in perturba-
tions in comparison with control. Most (86%) of these gene expression changes were associated with decreased chromatin 
interactions (green colors), with 1662 upregulated (dark green) and 1504 downregulated (light green). The remainder of the 
interaction changes (14%) were distributed between the other possible scenarios: increased interactions and expression (193, 
dark blue), increased interaction and decreased expression (154, light blue), no change in interactions and either an increase 
(71, dark orange) or decrease (67, light orange) in expression. C, Heatmap showing the number of significant (q<0.01) interac-
tions overlapping with differentially expressed genes; top 40 shared differentially expressed genes shown, sorted by number 
of significant interactions in CTRL (gene name labeling shows direction of expression, where green is up and red is down). 
D, Higher-resolution mapping of local neighborhood interactions for the example genes Nppa/Nppb, Kcnd2, and Mef2c gene 
loci +/–1 Mb (q<0.01). Lines revealing precise contact sites are color coded by q-value significance, with red being the most 
significant. RNA-seq tracks depict gene expression for CTRL (green), CTCF-KO (purple), and TAC (red). CTRL indicates control; 
KO, knockout; and TAC, transverse aortic constriction.
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CTCF-KO and TAC (Figure 4D, center). Last, a third class 
of regulatory scheme is represented by Mef2c, whose 
expression changes with neither CTCF-KO nor TAC, but 
which undergoes a high degree of splicing regulation23 
and is a central driver of cardiac gene expression24 (Fig-
ure 4D, right). This locus underwent a consistent de-
crease in chromatin interactions up- and downstream 
of the gene in CTCF-KO and TAC, suggesting a loosen-
ing of the local chromatin environment.
Enhancers are regions of the genome that positively 
influence gene expression and are identified on the 
basis of diagnostic histone posttranslational modifica-
tions. How enhancers are regulated in the 3-dimen-
sional context of the cardiac nucleus is unknown. Of 
previously identified enhancers from adult cardiac myo-
cytes,11 5050 contained significant Fit-Hi-C interactions. 
These enhancers consistently exhibited decreased inter-
actions after perturbation (Figure 5A). Indeed, 47% of 
enhancers exhibited decreased interactions in CTCF-KO 
and 67% of enhancers exhibited decreased interactions 
in TAC (Figure 5B, left and center). It is remarkable that, 
of the enhancers that were shared between the 2 con-
ditions, 85% showed a decrease of interactions in both 
CTCF-KO and TAC (Figure 5B, right). Figure 5C further 
illustrates that CTCF-KO and TAC were both associated 
with decreased enhancer-gene interactions (the direc-
tionality of gene expression change is reported in the 
different cohorts of enhancers from Figure  5B), and 
the affected genes were enriched in cardiac pathology 
pathways (Figure VIIIG in the online-only Data Supple-
ment). Rock2, previously implicated in cardiac disease,25 
is an example gene whose interactions with multiple 
enhancers are depleted in the setting of CTCF-KO or 
TAC (Figure 5D; Tables I through III in the online-only 
Data Supplement). These findings indicate that a global 
increase in chromatin fluidity around enhancers is a 
shared feature of cardiac pathology.
DISCUSSION
This study provides a resource of endogenous chro-
matin architecture in cardiac myocytes and describes 
the global changes in chromatin interactions during 
heart failure. With these data, the basal microenvi-
ronment of any genomic locus can be explored in the 
future, and changes in this microenvironment can be 
examined in the setting of pressure overload–induced 
heart failure. As a model of heart disease caused by 
increased afterload (including hypertension and aortic 
stenosis), TAC was used in this study to investigate 
how global changes in the epigenome participate in 
disease pathogenesis; the CTCF-KO mouse was used 
as a complementary tool to investigate the role of a 
critical chromatin structural protein. It is interesting to 
A B D
C
50
25
0
Figure 5. Three-dimensional interactions between enhancers and genes are restructured after pressure overload or 
CTCF-KO.  
A, Number of contact sites per cardiac enhancer are quantified (q<0.01; rows are top 50 enhancers sorted by number of inter-
actions). B, Top, enhancers in which the number of significant (q<0.01) interactions (determined by the Fit-Hi-C tool) increases 
(blue), decreases (red), or remains the same (gray) with CTCF-KO (Left), TAC (Center), and with consistent changes with 
CTCF-KO or TAC (Right). Darker shading indicates enhancers that interact with genes; lighter colors are regions not anno-
tated as coding. C, Number of genes that interact with enhancers from B, stratified by whether their expression is upregulated 
(green) or downregulated (red). Groupings are separated into enhancers whose number of overlapping interactions decreases 
(Left), increases (Middle), or remains the same (Right) after perturbation. D, Contact site mapping of interactions is shown 
for the example gene Rock2, which exhibits decreased interaction with enhancers in CTCF-KO and TAC, concomitant with 
decreased expression. CTRL indicates control; KO, knockout; and TAC, transverse aortic constriction.
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note that loss of CTCF or pressure overload–induced 
heart failure caused greater dynamics of endogenous 
chromatin structure and specific reorganization of en-
hancer-gene interactions. Depletion of CTCF resulted 
in a phenotype that shared some features of that in-
duced by pressure overload (including fibrosis, hyper-
trophy, changes in ejection fraction, and changes in 
chamber dimensions), although there were notable 
differences between these phenotypes (particularly in 
the extent of left ventricular dilation), meaning that 
CTCF-KO does not fully recapitulate and is thus not 
a model of pressure overload hypertrophy, but rather, 
is a form of dilated cardiomyopathy with hypertro-
phy and fibrosis. Human patients with heart failure 
treated with left ventricular assist devices to unload 
the heart demonstrated increased CTCF protein and 
mRNA levels. Although this observation is interesting, 
caution is warranted in the extrapolation of these 
findings to the clinical arena: future cohort studies in 
cardiomyopathies of distinct etiology will be required 
to fully understand the role of CTCF in human heart 
failure.
Although the pattern of chromosome organization 
during mitosis is well known, how the genome is struc-
tured during interphase or in cells that have exited the 
cell cycle has remained a mystery until very recently. In-
terphase nuclei form chromosomal territories (features 
mainly characterized by microscopy),26 which serve to 
segregate entire chromosomes apart from each other. 
The development of genome-wide DNA sequencing–
based approaches in the past few years has enabled 
the precise determination of subchromosomal genome 
architecture.8,18,27 This information, that is, how the 
genome is packaged in different cells, is important 
for basic science reasons (eg, to answer fundamental 
questions about the structure-function relationship 
between an invariant genome and a highly variable 
transcriptome [among different cells in a multicel-
lular organism]) and for translational implications, as 
well (eg, many diseases involve changes in epigenetic 
machinery, but understanding how these chromatin 
modifiers exert their control of disease phenotype re-
quires determination of the substrate on which they 
operate, ie, the structural conformation of the epig-
enome). With these considerations in mind, the pres-
ent study investigates each of the various levels of hi-
erarchical organization of cardiac chromatin including 
the formation of TADs and the compartmentalization 
of large swaths of the genome (Figure  2 and Figure 
VII in the online-only Data Supplement), intermediate 
structural features, including chromatin loops of vari-
ous lengths (Figure 3), precise remodeling of interac-
tions around genes involved in disease pathogenesis 
(Figure 4), and the structural organization of noncod-
ing functional units (ie, enhancers, which incorporates 
existing knowledge of posttranslational modifications 
decorating histones at specific genomic loci) near the 
genes they modify (Figure 5).
The present study and previous work in the field 
suggest that heart failure is associated with a plastic 
epigenome (Figure 6): widespread changes in boundary 
strength (Figure 2C); decreased formation of chromatin 
loops (Figure 3C and 3D); decreased interactions in local 
chromatin environment of differentially expressed genes 
(Figure 4); and more fluid interactions between enhanc-
ers and genes (Figure 5). These findings support previous 
studies of heart failure showing global DNA demethyl-
ation,28 altered histone stoichiometry and a decrease in 
heterochromatic posttranslational modifications,19,29,30 
activation of pathogenic noncoding RNAs,31,32 and ab-
errant transcriptional activation.3,4,33 Heart disease has 
been speculated to be the result of a reversion to more 
primitive gene expression programs2; the present find-
ings extend this hypothesis, identifying shared epig-
enomic features in response to cellular stress.
Although CTCF has been associated with TAD 
boundaries,34–36 its structural role has been unclear in 
postmitotic cells in vivo. The present study explores the 
role of CTCF in cardiac epigenome stability, but can-
not unequivocally conclude whether CTCF is dispens-
able for TAD maintenance, insofar as residual CTCF 
was present. A recent investigation, using an auxin-
inducible degron approach to deplete CTCF protein in 
mouse embryonic stem cells, demonstrated that near-
Figure 6. Model for epigenomic changes in develop-
ment and disease.  
Development is accompanied by changes in chromatin to 
endow terminally differentiated cells with stable transcrip-
tomes. Disease upsets this balance, transitioning select 
regions of the genome into more dynamic conformations 
through effects on chromatin structure, enhancer-gene 
looping, histone modifications, DNA methylation, and other 
factors. This model is based on findings from this article and 
previous publications2–5,10,11,15–17,29–33 as described in the text. 
NcRNA indicates noncoding RNA; TAD, topological associat-
ing domain; and TF, transcription factor. 
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complete depletion of CTCF was required to influence 
gross chromatin organization, with TAD structure still 
observed with as low as 4% of normal CTCF protein 
levels.37 In the present article, because many loops did 
not harbor CTCF, and a large number of loops with 
unchanged CTCF binding were altered in their confor-
mation, these findings support a model in which other 
factors stabilize chromatin looping and CTCF partici-
pates in gene regulation through mechanisms in addi-
tion to anchoring. Other insulator proteins (eg, cohes-
ins, which behave similarly to CTCF across a population 
of mice and are modestly downregulated in CTCF-KO 
mice [Figure IIIA in the online-only Data Supplement], 
suggesting that cohesins and CTCF are coregulated in 
circumstances of global chromatin remodeling) may 
stabilize TADs, in addition to histone H3 lysine 27 tri-
methylation (globally unchanged in CTCF-KO, Figure 
IIF in the online-only Data Supplement) and perhaps 
DNA methylation. CTCF is essential for development 
beyond embryo implantation,38 and longer-term deple-
tion in the heart was lethal (Figure IID in the online-only 
Data Supplement). This investigation demonstrates that 
subtle perturbations in the structure of gene expression 
domains can result in catastrophic malfunction of the 
myocyte and heart, in agreement with previous find-
ings implicating CTCF in disease-related transcription 
in other organs.39 Cell death in the heart is an active 
area of investigation,40 and, although our studies found 
no evidence for apoptotic cell death, it is possible, giv-
en the progressive nature of this phenotype, that the 
CTCF-KO cardiomyopathy is driven by more than one 
form of cell death to be determined in future studies. 
Our previous investigations41 showed that CTCF knock-
down was sufficient to induce cell death in HeLa cells 
but not in neonatal rat ventricular myocytes, and other 
investigations in noncardiac cells have suggested that 
aberrant CTCF function leads to abnormal cell death 
decisions, such as in cancer.42
Recent studies have identified a role for loops in 
the formation of chromatin neighborhoods to insulate 
against aberrant, and to coordinate synchronized, ex-
pression of genes.43 In addition, ChIP-seq investigations 
of histone marks have provided important insights into 
how these features correlate with gene expression.11 
With high-resolution chromatin conformation data, 
the more biologically relevant approach can be taken 
to examine enhancers in the circumambient context 
in which they operate.44 The present findings are a re-
source for examining gene regulation by virtually any 
known, or to-be-discovered, cardiac enhancer, and to 
explore newly identified 3-dimensional features of the 
cardiac nucleus.
In summary, these studies point to a common en-
tropic destination for pathologically disturbed chroma-
tin, supporting a model wherein chromatin structural 
abnormalities underpin the complex cellular networks 
that go awry in disease and providing a new conceptual 
framework to engineer therapies.
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Supplemental Material 
 
High resolution mapping of chromatin conformation in cardiac myocytes reveals 
structural remodeling of the epigenome in heart failure 
 
Rosa-Garrido et al. 
 
 
This section contains the extended Materials & Methods Section and Supplemental Figures 1-8. 
Supplemental Tables 1-3, containing enhancer-gene data, are uploaded as separate excel files. 
Sequencing data used in this paper have been deposited in NCBI with GEO accession number 
GSE96693. 
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MATERIALS & METHODS 
 
Hi-C Methodology 
For each replicate (n≥3 for all sequencing experiments in this paper), one million isolated adult 
cardiomyocytes were fixed in 1% formaldehyde and underwent in situ Hi-C as described,1 using 
MboI as the restriction enzyme. Hi-C libraries were sequenced on an Illumina HiSeq 4000 
instrument. Please see Figure S1 for detailed data on read counts, cis/trans interactions, and 
mappability. All sequencing data have been uploaded to NCBI with the GEO accession number 
GSE96693. 
 
Bioinformatics Analyses of Hi-C Data 
Raw paired-end 50bp reads were mapped to mm10 using BWA-MEM2 as recently described.3 
Raw genome-wide contact matrices were generated using a custom Perl script. To normalize 
genome-wide raw contact matrices, we first removed bin pairs that fell outside the 5th and 99.5th 
percentiles (that had abnormally low or high coverage, respectively). We then used a custom 
Perl script to perform iterative correction and eigenvalue decomposition (ICE) on the filtered 
matrices for 50 iterations.4 We then divided all entries in each genome-wide contact matrix by 
the corresponding matrix sum, and then multiplied them by the arbitrary value of 1 billion for 5kb 
resolution or 1 million for 40kb and 50kb resolution.5 For the main analyses in this study, all 
biological replicates were combined. 
For the individual replicate analyses, we generated replicate-specific contact matrices 
using the methods described above, and then calculated a Pearson correlation for the ice-
corrected and normalized cis bin pairs for which we measured interactions in each replicate 
pair. We then plotted log10(normalized interactions) for each replicate on a respective axis using 
the smoothScatter() function in R. Once we determined a high correlation between replicates, 
we pooled the 3 replicates of each sample type together. 
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To generate 40kb z-score matrices, we first generated 40kb normalized contact matrices 
from the combined replicates for each sample type, using the methodologies described above. 
Z-score cis matrices were then generated using the loess method,5 using the following function 
from the HiTC package6 in Bioconductor: normPerExpected(matrix, method=”loess”, 
span=0.005, stdev=T). Then, q-values were calculated using the zscore2pval.R script in 
https://github.com/dekkerlab/cworld-dekker. Significant q-values < 0.01 were used for 
downstream analyses and Circos plot generation in R. 
Identification of AB compartments at 5kb resolution was performed using the prcomp() 
function in R and correlating PC1 values to gene density. To generate a heatmap of difference 
in AB compartmentalization, we first determined the bins on autosomes that underwent 
compartment change in at least one sample. Then, we performed k-means clustering with k = 5. 
The AB difference graphs were generated using the following logic: If the PC1 value of a given 
bin of a diseased sample became more positive or less negative when compared to control, 
then the difference was deemed “positive” and the magnitude was shown in orange as a 
positive difference. Contrastingly, if the PC1 value of a given bin of a diseased sample became 
more negative or less positive, then the difference was deemed “negative” and the magnitude 
was shown in purple as a negative difference. To compare AB compartment changes with gene 
expression differences, we determined the AB compartmentalization for the TSS bin for each 
autosomal gene and then generated boxplots showing compartment change on the x-axis and 
log2(fold-change) of FPKM on the y-axis. 
Insulation scores were calculated using the method,5 using a 500kb sliding window 
across each 5kb normalized cis contact matrix. Insulation scores for all samples were 
normalized together using the normalize.quantiles() function of the preprocessCore package in 
Bioconductor (originally described7). The delta vector for each insulation score profile was 
generated using a custom R script, using a 500kb sliding window across each 5kb normalized 
contact matrix, and a 100kb outward distance to the left and right of each bin to calculate the 
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slope of the insulation score. Insulation boundaries were defined as local minima in the 
insulation score, and boundary strength was calculated. We discarded boundaries with strength 
< 0.1.5 Insulation boundary heatmaps were generated by first calculating the insulation 
boundaries that overlap between control and CTCF knockout, and between control and TAC. 
Then, we generated heatmaps of overlapping boundary strength changes per autosome. 
To call and visualize chromatin loops, we used Juicer8 and Juicebox.9 We first ran 
juicebox_tools_7.0 pre to generate .hic files for each condition, using reads with mapping quality 
≥ 10. We then used juicebox_tools_7.0 hiccups, a functionality of Juicer, to call loops on the .hic 
files, using default parameters. Juicebox v1.5 was used to visualize the data. We then utilized 
the InteractionSet library 10 for custom downstream analyses. 
 
Interaction Calling via Fit-Hi-C  
To call significant interactions in our 5kb cis interaction matrices, we used the 
Bioconductor version of Fit-Hi-C (https://bioconductor.org/packages/release/bioc/html/FitHiC 
.html)11 with the following parameters to analyze mid-range interactions up to 20Mb: 
distUpThresh=20000000, noOfBins=200. As input, we used concatenated raw autosomal 5kb 
cis interaction matrices and concatenated autosomal ICE bias vectors generated from our 
custom ICE implementation. After running Fit-Hi-C, we converted cis interactions with q-value < 
0.01 into InteractionSet10 format for interrogations of significant interactions using R. 
 
Data Visualization 
All visualizations of Hi-C data were generated either using custom R scripts written in house or 
using Juicebox.9 For custom visualizations, we used the Bioconductor package ggbio.12 
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RNA-seq Methodology 
Total RNA from isolated adult cardiomyocytes was isolated using the Qiagen RNeasy Mini Kit 
(Cat# 74104). RNA quality was assessed using the Agilent 2100 Bioanalyzer (Cat# G2940CA). 
Ribosomal RNA was then removed using an Illumina Ribo-Zero rRNA Removal Kit (Cat# 
MRZH11124) and the RNA-seq library was prepared at the UCLA Clinical Microarray Core 
using the KAPA Stranded RNA-Seq Library Preparation Kit (Cat# KK8401). The average insert 
size of each library was measured using an Agilent 4200 TapeStation (Cat# G2991AA). All 
libraries ranged from 200 to 400bp in length. RNA-seq libraries were sequenced on two lanes of 
an Illumina HiSeq 2000 to obtain 2x100bp (paired-end) reads. On average, ~50 million raw 
pairs were generated per library. 
 
Bioinformatics Analyses of RNA-seq Data 
Raw paired-end 100bp reads were sequenced on two lanes of an Illumina HiSeq 2000, and 
FASTQ files were demultiplexed using a custom Python script. Reads were mapped to the 
mm10 genome with TopHat v2.1.0,13 using mm10 bowtie2 indices and a reference GTF 
provided by iGenomes (Illumina, downloaded from Ensembl release 81 on July 17, 2015). 
Transcripts were assembled using Cufflinks14 v2.2.1 with the -G parameter (using the same 
GTF), and merged using the Cuffmerge feature of Cufflinks with the -g and -s parameters (using 
the same GTF and the reference FASTA provided by iGenomes, respectively).14, 15 Cuffquant 
(from Cufflinks v2.2.1) was performed to determine transcript abundances for all samples, using 
the -b parameter (with reference FASTA from iGenomes), and the --max-bundle-frags 5000000 
and -u parameters. Cuffdiff (also from Cufflinks v2.2.1) was used with identical extra parameters 
as Cuffquant to determine differential gene expression between conditions and assign p-values 
and q-values for each gene. Visualization of RNA-seq data was performed using 
cummerbund,16 ggbio,12 as well as custom R scripts. 
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ChIP-seq Methodology  
ChIP for CTCF (Active Motif Cat# 61311) was performed on pooled isolated cardiomyocytes 
(~10 million total), using the ChIP-IT High Sensitivity Kit as described.17 Cardiomyocyte pools 
were obtained from 3 control and 3 CTCF KO hearts. ChIP-seq libraries were prepared using 
the NuGEN Ovation Ultralow System V2 1–16 kit (Cat# 0344). 
 
Bioinformatics Analyses of ChIP-seq Data 
ChIP-seq libraries were sequenced on an Illumina HiSeq 2000 instrument. Raw single end 50 
bp reads were demultiplexed using a custom Python script and then mapped to the same mm10 
Ensembl reference genome as the RNA-seq data, but using Bowtie218 v2.2.6 with default 
parameters. Samtools19 v0.1.19 was used to convert SAM files to BAM format, and peak calling 
was performed using the macs2.1.1.2016.0309 callpeak function20 with default parameters. The 
CTCF ChIP BAM file was used as the treatment file and input BAM file as the control. A filtering 
step was added in R to only keep autosomal peaks. 
 
ChIP-seq Visualizations 
To visualize the distribution of CTCF peak occupancy across features of the mm10 genome, we 
used the ChIPseeker21 package in Bioconductor. We used ngs.plot22 to generate coverage 
heatmaps around TSSs and insulation boundaries. 
 
KEGG Analysis 
To determine the gene ontology of genes of interest, we used a custom R script that uses 
KEGG.db in Bioconductor,23 with custom visualization. 
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Cardiomyocyte Isolation 
Using an established protocol,24 adult mice were treated with heparin (100 USP units) for 20 
minutes to prevent blood coagulation, and then anesthetized with sodium pentobarbital (100µl 
of 50mg/ml dilution, intra-peritoneal). Upon loss of rear foot reflex, the heart was removed and 
instantaneously arrested in ice-cold phosphate buffered saline (PBS) and mounted on a 
modified Langendorff apparatus. After 5 min of perfusion with Tyrode’s solution (130mM NaCl, 
5.4mM KCl, 1mM MgCl2, 0.6mM Na2HPO4, 10mM glucose, and 10mM HEPES, pH 7.37, 
oxygenated with 95% (v/v) O2-5% (v/v) CO2) at 37°C, the heart was perfused for 15-30 min with 
30 ml Tyrode’s containing 20mg collagenase type-II and 3mg protease type-XIV and then 
washed for an additional 10 min with Krebs buffer (KB) (25mM KCl, 10mM KH2PO4, 2mM 
MgSO4, 20mM glucose, 20mM taurine, 5mM creatine, 100mM potassium glutamate, 10mM 
aspartic acid, 0.5mM EGTA, 5mM HEPES, pH 7.18) oxygenated with 95% O2-5% (v/v) CO2. 
Cardiomyocytes were dissociated in KB solution, filtered (100µm strainer) and centrifuged 2 min 
at 1000xg for further usage. This method obtained cells that were ≥95% cardiomyocytes by 
visual inspection of rod-shaped cell morphology. 
 
Post-mortem histology, Cell Size Quantification and Fibrosis Detection 
Whole hearts were rapidly excised from animals, perfused with 0.1 M potassium (K+) solution, 
fixed using 4% paraformaldehyde and then embedded in paraffin. Hearts were sectioned into 
4µm thick sections. Cell size was determined using NIS-Elements Advanced Research v4.0, on 
heart slices labeled with wheat germ agglutinin (Thermo Fisher Scientific Cat# W11262). 
Fibrotic tissue was visualized using the Abcam Picrosirius Red Stain Kit (Cat# ab150681). 
 
CTCF Knockout Mouse Generation 
Ctcf-floxed (Ctcfflox) mice, in which loxP sites flank exons 3–12, were previously reported.25 The 
floxed allele occurs in the C57BL/6 background. To generate cardiac Ctcf cKO mice, we 
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crossed Ctcfflox/flox mice with transgenic mice expressing the α-myosin heavy chain promoter that 
directs expression of a tamoxifen-inducible Cre recombinase (MerCreMer).26 Adult Ctcfflox/flox x α-
MHC-MCM+/- mice (8 weeks) were administered tamoxifen (Tx) in the chow (0.4mg/g) for 5 
weeks plus 1 week on normal chow to deplete CTCF.  
 
Transverse Aortic Constriction and Echocardiographic Measurements 
All animal studies were approved by the UCLA Animal Research Committee in compliance with 
the NIH Guide for the Care and Use of Laboratory Animals. Only adult mice were used in this 
study. Adult C57BL/6 male and female mice were subjected to transverse aortic constriction 
surgery to induce pressure overload and cardiac function was measured before, directly after 
and once every 5 days for the duration of the experiment as described.27 Animals were 
sacrificed for experiments based on changes in ejection fraction and heart to body weight, 
indicating the presence of pathology.  
 
Human Samples 
All human samples used in this study were procured in the Ronald Reagan Medical Center at 
UCLA following patient consent according to IRB#11-001053-AM-00016. mRNA and protein 
were isolated from LVAD biopsy cores or explanted hearts using conventional approaches.  
 
Electrophoresis and Western Blotting 
Cardiomyocytes, neonatal rat ventricular myocytes or human heart tissue were lysed (50mM 
Tris pH 7.4/10mM ethylenediaminetetraacetic acid [EDTA]/1% Sodium dodecyl sulfate 
[SDS]/0.1mM phenylmethanesulfonylflouride/protease inhibitor cocktail pellet (Roche)/0.2mM 
sodium orthovanadate/ 0.1mM sodium fluoride/10mM sodium butyrate), sonicated, and 
separated via SDS-PAGE using Laemmli buffer. Detection was performed on the LI-COR 
odyssey. Antibodies were as follows: CTCF mix 1:500 (Abcam, ab70303), (Abcam, ab128909), 
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(BD, 612148), (Abiocode, R3171-1), (Diagenode, C15410210-50) and (Active Motif, 61311), 
H3K27me3 1:1000 (Abcam, ab6002), H3K4me3 1:1000 (Abcam, ab8580), Rad21 1:1000 
(Abcam, ab992), GAPDH 1:1000 (Santa Cruz Biotechnology, sc20357), Actin 1:1000 (Santa 
Cruz Biotechnology, sc1616), secondaries 1:10,000 (LI-COR, IRDye conjugated). Relative 
quantification for CTCF expression normalized with respect to Actin was performed using 
ImageJ software. 
 
RNA Isolation and qPCR 
RNA from left ventricular adult cardiomyocytes were isolated using TRIzol (Thermo Fisher 
Scientific, 15596018) according to the manufacturer's protocol. cDNA was synthesized using 
iScript cDNA Synthesis Kit (Bio-Rad, 170-8891). qPCR was performed using SsoFast 
EvaGreen Supermix (Bio-Rad, 172-5201) on a BioRad, C1000 thermocycler.  
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SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1. Genome-wide chromatin conformation capture datasets and 
quality control analysis for Hi-C and RNA-seq. (A) Table summarizing read counts and 
mapping statistics for each sample type. Replicates of the same condition were combined upon 
verification that interactions and AB compartmentalization correlated with Pearson correlation > 
0.90 (at 5kb resolution). (B) Coverage histograms of raw 5kb cis and trans matrices for each 
sample type (x axis indicates number of raw interactions and y axis indicates the number of bins 
that had such number of interactions). (C) Normalized interaction frequency per bin is highly 
conserved between biological replicates, Pearson correlation coefficient of > 0.95 in all 
comparisons. For this analysis, cis interactions ≤ 2Mb were compared. The normalized cis 
matrices were generated from ice-normalized cis and trans genome-wide matrices that were 
divided by matrix sum and multiplied by the arbitrary value of 1 million. (D) Summary statistics of 
RNA-seq sequencing data, including number of mapped read pairs for each sample. 
 
Supplemental Figure 2. Generation and phenotypic characterization of cardiac-specific 
CTCF knockout mice. (A) Left, diagram showing the floxed ctcf gene from exon 3 to 12. 
Labeled yellow bars mark exons 1 to 12 and labeled green arrows indicate primers used to 
verify CTCF depletion via PCR. Primers p8563 and Skas1 should have a PCR product when 
exons 3 to 12 are excised by the Cre recombinase via the LoxP sites (blue triangles), and 
Primers p8563 and p8946 should have a PCR product in any scenario in which the Cre 
recombinase is not expressed. Right, α-MHC-Cre+/- x CTCFflox/flox mice were fed Tx containing 
chow (0.4mg Tx/g chow) for 5 weeks and then switched to normal chow for 1 week, resulting in 
deletion of exons 3-12 of CTCF. α-MHC-Cre+/- x CTCFflox/flox mice fed normal chow for 6 weeks, 
and α-MHC-Cre+/- x CTCFWT/WT mice fed tamoxifen chow for 5 weeks plus 1 week on normal 
chow, served as controls. (B) PCR genotyping confirms the presence of the floxed CTCF alleles 
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in our CTCFflox/flox Cre+/- mice (left), as well as presence of the Cre gene in these mice (center). 
After 5 weeks of tamoxifen treatment followed by 1 week on regular chow, gene excision in the 
heart was confirmed by PCR using p8563 and Skas1 primers (right). PCR amplified bands at 
~500bp in the knockout (red arrows), but did not amplify the ~27kb region of the floxed allele in 
Cre-/- control mice (white arrows) or normal chow fed mice (black arrows). (Rg) regular chow. 
(C) CTCF KO was confirmed by RT-qPCR (left panel) for α-MHC-MCM+/- x CTCFflox/flox mice that 
were fed tamoxifen for 1, 2, 3, 4, 5 and 6 weeks. Blue bars show fold enrichment when 
compared to CTRL, and error bars indicate standard deviation; * indicates p<0.05 Student’s t-
test. (D) Kaplan-Meier survival curves of CTCFflox/flox Cre+/- (n=20) (red line), CTCFwt/wt Cre+/- 
(n=10) (green line), CTCFflox/flox Cre-/- (n=10) (blue line) fed with Tx and CTCFflox/flox Cre+/- (n=10) 
(orange line) fed with regular chow. Left panel, 5 weeks after Tx treatment, mouse survival 
decreased 63%, while survival dropped to 8% at 6 weeks. Right panel, Mouse survival stabilizes 
at 53% after the initial 5 weeks when mice are returned to normal chow. (Rg) regular chow. (E) 
RT-qPCR revealed mRNA down-regulation of SERCA (Atp2a2) and α-MHC (Mhy6), and 
upregulation of ANF (Nppa) and β-MHC (Mhy7), in mice undergoing 5 weeks Tx treatment plus 
1 week regular chow (Rg). Bars show fold enrichment when compared to CTRL mouse given 
regular chow, and error bars indicate standard deviation; * indicates p<0.05 Student’s t-test. (F) 
Western blot confirming CTCF depletion in tamoxifen-treated CTCFflox/flox Cre+/- mice (left), and 
showing no change in H3K27me3 and H3K4me3 with CTCF depletion. Quantification of 
average relative CTCF intensity shows a decrease in CTCF protein levels in CTCFflox/flox Cre+/- 
mice after 5 weeks of tamoxifen treatment. (G) Representative hematoxylin and eosin staining, 
comparing CTCFwt/wt Cre+/-, CTCFflox/flox Cre-/-and CTCFflox/flox Cre+/- after 5 weeks Tx treatment 
followed by 1 week on regular chow. CTCFflox/flox Cre+/- treated with regular chow for 6 weeks 
were used as an extra negative control while TAC samples were used as a positive control for 
disease. Considerable dilatation of the ventricles is observed in the tamoxifen-treated 
CTCFflox/flox Cre+/- mice as well as the TAC mice. n = 5 for each condition. (lv) left ventricle, (rv) 
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right ventricle, (Rg) regular chow. Scale bar: 1mm. (H) Echocardiographic measurements of all 
the mice used in the study. Notably, CTCFflox/flox Cre+/- mice treated with tamoxifen had a 
pathological phenotype when compared to the CTCFflox/flox Cre+/- or CTCFwt/wt Cre+/- that were 
given regular chow as well as the CTCFwt/wt Cre+/- or CTCFflox/flox Cre-/- mice treated with 
tamoxifen. n = 8-17 depending on the survival rate for each condition. Line indicates mean 
value for the parameter of interest while the error bars indicate standard deviation. (EF) ejection 
fraction, (LVIDd) LV internal diameter at diastole, (LVIDs) LV internal diameter at systole. (I) 
Representative B-mode (left) and M-mode (right) echocardiography images at 6 weeks from 
normal chow CTCFflox/flox Cre+/- (upper panel) or tamoxifen fed CTCFwt/wt Cre+/-, CTCFflox/flox Cre-/-
and CTCFflox/flox Cre+/- mice. CTCFflox/flox Cre+/- mice show pathological phenotype as in (H); a 
TAC mouse is shown for comparison. 
 
Supplemental Figure 3. CTCF expression is down-regulated by pathologic stress and 
inversely correlated with heart size. (A) CTCF levels in mice undergoing a model of 
isoproterenol-induced heart failure across 87 genetically distinct strains. CTCF mRNA levels 
decrease across 80% of the mouse strains after isoproterenol treatment (top and middle panels; 
data from 28). Cohesin subunit Smca1 shows coordinate regulation with CTCF in this model. (B) 
Phenotype data from 87 mouse strains treated with ISO are plotted against CTCF mRNA 
expression after ISO. Total heart mass, left ventricular mass, and right ventricular mass all show 
significant negative correlation with CTCF expression, while ejection fraction shows no 
correlation. p-values were calculated using the Pearson correlation coefficient. (LV) left 
ventricle, (RV) right ventricle (data from 28). (C) Expression levels of different cohesin subunits 
decrease after CTCF depletion and TAC (log10(FPKM+1).  
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Supplemental Figure 4. Cardiac disease associated genes differentially expressed after 
CTCF depletion. Real time qPCR measuring expression levels of different cardiac genes after 
1, 2, 3, 4 and 5 weeks Tx treatment. Mice fed with regular chow (No Tx) and those fed with Tx 
were used as controls. Red and blue coloring indicates down- or up-regulation, respectively. 
(n=4/group; * p<0.05, Student’s t-test). 
 
Supplemental Figure 5. CTCF depletion does not promote apoptosis. Cleaved caspase-3 
staining of heart sections from CTRL and CTCF KO mice. Human sarcoma tumor cells were 
used as a positive control (Right panel). 
 
Supplemental Figure 6. Human subject clinical data. Available data on patients from whom 
heart samples were obtained is provided. “Wb quantitation” is the CTCF protein level measured 
by Western blot expressed as a ratio of after to before LVAD. NICM, non-ischemic 
cardiomyopathy; ICM, ischemic cardiomyopathy; NYHA, New York Heart Association 
Classification; EF, ejection fraction at time of LVAD placement. 
 
Supplemental Figure 7. Differences in boundary strength and A/B compartmentalization 
per chromosome. (A) Boundary strength differences between groups (red, higher; blue, lower; 
Insets: example region on chromosome 16. (B) Percent of genome-wide A/B compartment 
change with CTCF depletion (left) and TAC (right). Bottom panels highlight only bins that 
change compartment. 
 
Supplemental Figure 8. Implications for cardiac phenotype from chromatin structural 
changes in TAC and CTCF-KO cardiac myocytes. (A) Principal component analysis of the 
shared insulation boundary strengths. (B) Number of new boundaries between different 
experimental groups. Analyses do not distinguish between boundaries that emerge either from 
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shifting of an existing boundary outside the analysis window (+/-5kb from CTRL boundary 
center) or de novo formation of a completely new boundary. Color codes: Boundaries only found 
in CTRL (blue), only found in perturbation (beige), and shared between CTRL and perturbation 
(pink). (C) Principal component analysis of the RNA-seq samples. Control separates from CTCF 
KO and TAC on PC1. (D) KEGG pathway analysis of up-regulated (top) or down-regulated 
(bottom) genes bound by CTCF. Terms highlighted in green are cardiac-related. (E) KEGG 
pathway analysis of genes (2570; Figure 3F) that lie within the loops that lose ≥1 CTCF peak in 
CTCF-KO. (F) KEGG pathway analysis of genes (Figure 3H, “lost loops”) that lie within the 151 
enhancer-promoter loops that are lost in CTCF-KO (left), the 174 lost with TAC (middle), and 
the 114 loops lost in both diseased conditions (CTCF-KO and TAC; right). (G) KEGG pathway 
analysis of the differentially expressed genes (Figure 5C, “enhancers with decrease in 
interactions”) interacting with enhancers that lose interactions after perturbation (left, control vs. 
CTCF-KO; middle, control vs. TAC; right, shared). 
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CTCF KO CTRL Positive CTRL 
50µm 
Supplemental Figure 5. 
Sample	 Management	 Sex Age (Year) Etiology EF 
Wb quantification 
(After / Before) 
LVEDD 
(mm) 
NYHA 
class 
BNP 
(pg/mL) Comorbidities	 Medical History	 Medications	
114	 Before 	LVAD	
Male 
 43 NICM 25 2.12 
69	 4	 402	
None noted	
Dyslipidemia	
Atrial fibrillation	
Pravastatin	
Cardizem	
119	 After LVAD 	(7 weeks)	 45	 2	 73	
167	 Before 	LVAD	
Male	
 	 55	 NICM	 20	 2.54 
70	 4	 778	
COPD due to 50 
years of smoking 
history	
Adenoidectomy	
Non sustained ventricle 
tachycardia	
Heparin induced 
thrombocytopenia	
Amiodarone 
Epinephrine 
Alteplase	
177	 After LVAD 	(8 weeks)	 45	 2	 59	
141	 Before 	LVAD	
Male	
 	 65	 ICM	 20	 1.14 
65	 4	 548	
STEMI	
Type 2 DM	
Arthritis	
Hypertension	
Coronary artery disease	
Amlodipine 
Atorvastatin 
Hydralazine 
Metoprolol 	
Sildenafil 
Spironolactone 
Warfarin	
161	 After LVAD 	(24 weeks)	 40	 2	 57	
117	 Before 	LVAD	
Male	
 	 55	 ICM	 20	 1.12 
68	 3B	 402	
Type 2 DM	
Renal insufficiency 
Dyslipidemia	
Hypertension	
Acute Pancreatitis	
Colitis	
Amlodipine 
Furosemide 
Pravastatin	
181	 After LVAD 	(51 weeks)	 42	 2	 66	
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